S*Bio
10 Science Park Road
#03-18 The Alpha
Singapore Science Park #2
117684
Tel: 65-6827-5000
Fax: 65-6827-5005
Website: http://www.sbio.com/
Email: hr@s-bio.com
37 articles about S*Bio
-
Week in Review: Singapore's S*Bio Sells Cancer Drug to US Pharma
8/13/2012
-
S*Bio of Singapore Sells Cancer Drug Rights to MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) for $75 Million
8/10/2012
-
Cell Therapeutics, Inc. Pays $30 Million in Cash and Stock for S*Bio’s Selective JAK2 Inhibitor
4/19/2012
-
S*Bio's Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies For Patients with Myelofibrosis (MF)
11/22/2011
-
S*Bio to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
10/25/2011
-
Additional Data From Multiple Phase 1 and 2 Studies of S*Bio's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
6/1/2011
-
S*Bio Restructures $550 Million Agreement With Onyx Pharmaceuticals, Inc. for JAK2 Inhibitor Program
5/4/2011
-
S*Bio Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
4/14/2011
-
S*Bio's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
2/28/2011
-
S*Bio's Oral Histone Deacetylase (HDAC) Inhibitor SB939 Shows Tolerability and Safety in Phase 1 Clinical Trial in Patients with Advanced Hematologic Malignancies
12/7/2010
-
S*Bio's Novel JAK2 Inhibitor SB1518 Is Shown to Be a Safe and Effective Therapy in Phase 1/2 Studies For Patients with Symptomatic Myelofibrosis and Relapsed/Refractory Lymphoma
12/6/2010
-
Fourth Compound from S*Bio, Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies
11/22/2010
-
S*Bio's JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission for the Treatment of Myelofibrosis
10/18/2010
-
S*Bio Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939 for the Treatment of Recurrent or Metastatic Prostate Cancer (HRPC)
9/27/2010
-
S*Bio Announces US$5 Million Investment by Mitsui Ventures
9/23/2010
-
S*Bio Presents Positive Safety and Tolerability Results for Its Novel Oral JAK2 Inhibitor SB1518 From a Phase 1/2 Study for the Treatment of Myelofibrosis (MF)
6/14/2010
-
S*Bio Completes Enrollment of Patients in Phase 2 Clinical Trials for its JAK2 Inhibitor SB1518
6/9/2010
-
S*Bio and Onyx Pharmaceuticals, Inc. Announce Expanded Development Collaboration for JAK2 Inhibitors; S*BIO Lands Another $20 Million
5/5/2010
-
S*Bio Receives BioSingapore's 2009 Award for the Most Successful Bio-Partnership in Asia
3/18/2009
-
S*Bio Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award
3/6/2009